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Introduction: Triple-negative breast cancer (TNBC) lacks estrogen and progesterone receptors and does not
overexpress HER2. It displays a distinct clinical behavior. This study aims to assess the clinical, molecular and
prognostic characteristics of TNBC patients.
Patients/Methods: TNBC patients, referred to a tertiary medical center, 1/1/2000 – 31/12/2005, were included.
Clinical, molecular and prognostic characteristics were retrospectively collected from patients’ records.
Results: Overall, 122 consecutive TNBC patients were included with a median age of 54 years. Among the TNBC
patients, 101 (82.8%) were Jews and 21 (17.2%) were Arabs.
Family history for breast cancer was reported in 30 patients (24.6%). Genetic counseling was conducted in 30
patients (24.6%); 22/30 (73.3%) had BRCA1/2 mutations.
Median tumor size was 2 cm and positive lymph nodes were detected in pathological examination in 40 patients
(34%). At the time of data analysis, 21/118 patients (17.8%), who initially presented with early disease, had
developed metastasis. Local recurrence was detected in four patients (3.4%). The overall survival (OS) was
significantly longer for patients younger than 60 years compared to those ≥ 60 years, (Hazard ratio (HR) =2.1,
p=0.046). Nulliparous patients had significantly higher OS than patients with a reproductive history of ≥ 4 children.
(HR=0.31, p= 0.041). Mortality rate was higher for Arabs versus Jews but did not reach significance, (HR=1.33;
P=0.64).
Conclusions: TNBC represents an exclusive clinical behavior. Older age and parity were found to be poor prognostic
factors. Further larger studies are needed to reaffirm our findings and explore the genetics among non-BRCA1/2 TNBC
patients.
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Breast cancer is the most commonly occurring female
malignancy and the second most common cause of
death from cancer (DeSantis et al. 2011). It is well-
established that breast cancer is a heterogeneous disease
that encompasses various histopathological subtypes ac-
cording to the Perou-Sorlie classification. This classifica-
tion identifies different immunohistochemical biomarkers:
estrogen receptor (ER), progesterone receptor (PR),* Correspondence: karama_a@msn.com
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reproduction in any medium, provided the orighuman epidermal growth factor receptor (HER) 2, and the
Ki-67 proliferation index (Sørlie et al. 2001). It identifies
subtypes with a distinct clinical course and prognosis
(Hammond et al. 2010).Triple-negative breast cancer
(TNBC) is negative for ER, PR and HER2 (Ribelles et al.
2013).
TNBC constitutes approximately 10–20% of breast
cancer patients and represents an aggressive subtype
with a poor overall prognosis (Carey et al. 2010; Foulkes
et al. 2010). Moreover, TNBC patients have a higher rate
of early recurrence and distant metastasis to brain and
lungs compared to other breast cancer subtypes (Carey
et al. 2010). A high percentage of women with TNBCger. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
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(Dent et al. 2007).
In addition to histopathological subtypes, the clinical
course might be affected by the molecular genetic pro-
file, including the germ-line mutation of the genes
BRCA1 and BRCA2 (Badve et al. 2011). The interplay
between BRCA mutations and TNBC is complex. Most
breast tumors displaying BRCA1 mutations are TNBC
(Atchley et al. 2008). Furthermore, BRCA1-deficient tu-
mors share biological characteristics with TNBC (Choo
& Nielsen 2010).
To the best of our knowledge, only scant literature has
tried to explore the prevalence of BRCA 1/2 mutations
among women with TNBC of different ethnic groups
(Comen et al. 2011). Greenup et al. found that the
prevalence of BRCA1 mutations was significantly higher
among Ashkenazi Jewish women diagnosed with TNBC,
as compared to African-American patients (Greenup
et al. 2013). In Israel, a country with diverse and unique
ethnic groups, there has been no attempt to characterize
TNBC patients. The aim of the current study was to il-
lustrate the clinical, molecular and prognostic character-
istics of women with TNBC in Israel.Patients and methods
A retrospective review of the medical records of TNBC
patients referred to a tertiary medical center (Rambam
Health Care Campus, Haifa, Israel) between 1/1/2000
and 31/12/2005 was performed. Clinical data, molecular
characteristics, treatment approaches and clinical data at
follow-up visits were retrieved. Patients were divided
into two main groups according to ethnicity: Arabic (A)
and Jewish (J). ER, PR and HER2 status was extracted
from routine pathology reports, and BRCA1/2 mutation
status was obtained from genetic counseling reports.
Follow-up clinical data included information about
recurrent disease categorized as local, distant, or
combined sites. Patients who presented initially with
metastasis were not included in the recurrence pa-
rameters measurements.Statistical analysis
Statistical analysis was performed with SPSS package
version 21. Descriptive statistics in terms of mean, median
range, and percentiles were applied to all parameters.
Quantitative parameters were summarized by mean ±
standard deviation (SD) and examined using T-test or
Mann–Whitney U test. Categorical parameters were sum-
marized using frequency measures, and statistical analysis
was performed using Fisher exact test. Survival analysis
was performed with Log rank test. Cox regression model
was used to determine the association between overallsurvival and several independent parameters. A p value
of <0.05 was considered as statistically significant.
Results
Overall, 122 consecutive TNBC patients were included
in the study. The clinical, molecular, and histopatho-
logical characteristics of the TNBC patients are pre-
sented in Table 1. A majority of patients (74.6%) were
younger than 60 years of age, and the median age was
54 years (range, 27–93 years). A total of 101 (82.8%) pa-
tients were Jewish (J) and 21 (17.2%) were Arabic (A).
Reproductive history was examined according to the
number of children at diagnosis and patients were di-
vided into three subgroups, with the majority (54.5%) of
TNBC patients having 1–3 children (Table 1).
With regard to inheritance, 1st degree family history
for breast cancer was reported in 30 (24.6%) patients.
Genetic counseling was conducted for these 30 patients,
22 of whom (73.3%) were positive for BRCA1/2 muta-
tions. These patients represented 18% (22/122) of all the
women included in the study.
Histopathological studies demonstrated that infiltrat-
ing ductal carcinoma (IDC) was the prominent histo-
pathological type (115/122, 94.3%). Tumor size showed
variability, with a median tumor size of 2 cm (range, 0–9
cm). Resected lymph nodes were positive for breast
tumor by pathological examination in 40 (34%) patients.
Lumpectomy was the most common approach, per-
formed in 76.6% patients. However, mastectomy was
performed in nearly one-quarter of the patients.
Adjuvant chemotherapeutic treatment was given to 85
(81%) patients, while 11 patients received neoadjuvant
therapy and, accordingly, were excluded from the treat-
ment measurements.
Tumor progression was designated as metastasis de-
velopment, local recurrence, or a combination of both.
At the time of data analysis, 21/118 (17.8%) patients,
who initially presented with early disease, had developed
metastasis. Four patients who had metastatic disease at
presentation were excluded. With regard to the location
of the metastasis, the major metastatic sites included
bone in 7 (33.3%), liver in 5 (23.8%), lung in 7 (33.3%),
and central nervous system in 3 (14.3%). Local recur-
rence was detected in four (3.4%) patients. The time
elapsed between diagnosis and recurrence was wide,
with a median of 2.5 years (range, 0.25-11 years).
Within a follow-up period of 0.14-14 years following
diagnosis, death of any cause was observed in 35
(28.70%) patients (Table 2).
Association of clinical parameters with overall survival
(OS)
We first explored the relationship between OS and dif-
ferent univariate analyses (Table 3). Interestingly, the
Table 1 Clinical, molecular and histopathological
characteristics of triple-negative breast cancer patients
Characteristic N Percentage of total (%)
Age
>60 years 31 25.40









1st degree family history
Positive for breast cancer 30 24.60





Invasive ducal carcinoma 115 94.30
Medullary carcinoma 3 2.45
Infiltration lobular carcinoma 4 3.28
Involved lymph nodesa
Absent 78 66
1-3 nodes 27 23
≥4 nodes 13 11
Tumor size
≤2 cm 66 54.00








aExact number of involved lymph nodes missing in four patients.
bFour patients who had metastatic disease at presentation were not included
in surgical and chemotherapy treatment.
cAdjuvant treatment data was missing for two patients, 11 patients received
neoadjuvant treatment.
Table 2 Clinical outcomes of triple-negative breast cancer
patients






















a Four patients had metastatic disease at presentation. These patients were
not included in the recurrence measurements.
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patients younger than 60 years, compared to those over
60 years (Figure 1). Notably, the overall survival for
those with a reproductive history of ≥4 children was sig-
nificantly lower than for TNBC patients without chil-
dren. Similarly, the risk of mortality among TNBCpatients with four or more children was higher com-
pared to patients with 1–3 children (Figure 2).
Additional data from multivariate analysis demon-
strated that patients over 60 years of age had a higher
mortality risk when compared to patients younger than
60 years of age (p = 0.015). Moreover a patient with one
child or more had a higher risk of 4.9 folds for death
when compared to women with no children (p = 0.034)
(Table 3).
Discussion
Several studies have illustrated the clinical and molecu-
lar characteristics of TNBC and showed that, unlike
other breast cancer subtypes, TNBC is distinct because
of lower disease-free survival, higher predisposition to
form metastasis, and overall poor prognosis (Foulkes
et al. 2010). We hereby provide the first study which
aims to characterize TNBC patients in Israel according
to molecular and clinical parameters. In the current
study, we demonstrated that TNBC is more common
among patients younger than 60 years. This finding is in
accordance with previous literature. Dent et al. found
that the mean age of TNBC women at diagnosis was 53
Table 3 Hazard ratio of overall survival and risk of death, according to different clinical and histopathological
characteristics
Univariate Analysis
Characteristic Hazard ratio 95% confidence interval p value
Age
>60 years vs ≤60 years 2.1 1.01-4.38 0.046
No. of children
0 vs 4+ 0.31 0.098-0.953 0.041
1-3 vs 4+ 0.30 0.18-0.86 0.02
1+ vs 0 1.81 0.63-5.2 0.27
Ethnicity
Arabic vs Jewish 1.33 0.40-4.42 0.64
Family history
Positive vs negative for breast cancer 0.96 0.42-2.17 0.92
Lymph nodes
Positive vs negative 2.45 1.07-5.60 0.033
Tumor size
>2 cm vs ≤2 cm 1.46 0.68-3.10 0.33
Surgery
Mastectomy vs lumpectomy 1.45 0.63-3.33 0.38
Distant metastasis
Yes vs no 7.06 3.27-15.28 <0.001
Multivariate Analysis
Characteristic 95% confidence interval p value
Age
>60 years vs ≤60 years 1.335-14.986 0.015
No. of children
0 vs 1+ 1.129-21.920 0.034
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lar pattern with a median age of 52 years among TNBC
at diagnosis (Thike et al. 2010), while other histopatho-
logical breast cancer subtypes are generally diagnosed at
an older age (Boyle 2012).
We found that age younger than 60 years, nulliparity
and absence of metastasis were associated with a statisti-
cally significant longer overall survival. It should be
mentioned that only a few studies to date have examined
age as an independent prognostic factor affecting clinical
outcome among TNBC patients. Ovcaricek et al. re-
ported a significantly higher risk of relapse for patients
older than 65 years compared to those younger than 65
(Ovcaricek et al. 2011). Nevertheless, no significant dif-
ferences were noticed in OS between the two groups.
There are very few data regarding the relationship be-
tween hormone receptor profile, including TNBC, and
classical risk factors (Boyle 2012), with the assumption
that differences in histopathological subtypes mightexplain the distinct or contradicted susceptibility of
these subtypes to different risk factors.
Most interestingly, the interplay between parity status
and TNBC incidence and clinical course was investi-
gated. Phipps et al. showed a lower incidence of TNBC
among nulliparous women, with the number of births
positively correlated to the risk of TNBC (Phipps et al.
2011). These findings were corroborated by Nagatsuma
et al. who reported a significant correlation between Jap-
anese patients who had given birth most recently to
higher rates of advanced stages of breast cancer, with an
increased risk of negative estrogen and progesterone re-
ceptors and TNBC tumors when compared with nul-
liparous patients or those who had given birth less
recently (Nagatsuma et al. 2013). Furthermore, signifi-
cantly shorter overall survival rates were observed in pa-
tients with a more recent reproductive history when
compared to patients with less recent parity (Nagatsuma
et al. 2013). We showed that overall survival was
Figure 1 The overall survival of TNBC patients stratified by age at diagnosis (p = 0.042).
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tients and correlated inversely with the number of
births.
TNBC incidence varies among different ethnicities,
suggesting that there are different genes that can predis-
pose specific races to TNBC and distinct clinical behav-
ior (Boyle 2012; Stead et al. 2009; Kurian et al. 2010;Figure 2 The overall survival of TNBC patients stratified by number o
Between 1–3 vs 0: p = 0.59.Amirikia et al. 2011; Huo et al. 2009). For instance,
Stead et al. showed that TNBC was more prevalent
among African-American women compared to White
women (Stead et al. 2009). In addition, the lifetime risk
of TNBC was highest among African-American women
compared with Asian Hispanics and Whites in California
(Kurian et al. 2010). In our study, however, ethnicity wasf children. Between 0 to 4+: p = 0.033. Between 1–3 vs 4+: p = 0.012.
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bution of the patients matched the percentages in the
general population, the small number of Arabic patients
(17.2%), where the majority was Jewish patients, might
preclude obtaining significant different results according
to ethnicity.
It is well-known that the majority of breast cancers
that present in patients with positive BRCA1 mutations
are TNBC (Atchley et al. 2008; Musolino et al. 2007).
Moreover, recent studies showed that BRCA1-deficient
tumors possess similar biological characteristics to TNBC
(Choo & Nielsen 2010). Despite this significant clinical
and biological association, the clinical ramifications and
prognostic value of BRCA mutations in TNBC subgroups
are not established yet (Lee et al. 2011). Lee et al. tried to
illustrate the clinical outcomes according to BRCA status
among TNBC patients. This study showed similar survival
rates for carriers and non-carriers of BRCA mutations
(Lee et al. 2011). In addition, a large study conducted by
the Israel National Cancer Registration Center reported
no significant differences among BRCA and non-BRCA
patients of breast cancer (Rennert et al. 2007).
The prevalence of BRCA mutations among TNBC pa-
tients reported in the literature is 10-30% (Evans et al.
2011; Gonzalez-Angulo et al. 2011), while generally al-
most 10% patients diagnosed with breast cancer have a
BRCA mutation (Frank et al. 2002). In this study, BRCA
mutations were present in 22 patients (18% of all pa-
tients). Furthermore, BRCA mutation prevalence com-
prised a 53.3% (16/30) of patients with a 1st degree
family history of breast and/or ovarian cancer. These
current results coincide with earlier results on early on-
set breast cancer study in Israeli populations, showing
BRCA mutations that reached 31% in entire group, but
57% in patients with a family history of breast and/or
ovarian cancer (Gershoni-Baruch et al. 2000). However,
to the best of our knowledge, our study is the first to re-
port the prevalence of BRCA mutations among Israeli
TNBC patients.
In Israel, genetic counseling is recommended for early-
onset premenopausal Ashkenazi Jewish breast cancer pa-
tients and a familial history of breast or ovarian malignancy,
regardless of histopathological subtype.
Kwon et al. reported significant results that sup-
ported routine testing of TNBC patients younger than
50 years as a cost-effective strategy, since this strategy
provided an additional life expectancy for TNBC pa-
tients (Kwon et al. 2010). However, no worldwide val-
idated policy exists yet.
Our study has several limitations. Firstly, the small co-
hort studies precluded the power to detect significant
differences regarding the effect of race on the clinical be-
havior of TNBC patients. Secondly, only a small number
of patients underwent genetic counseling and muchsmaller numbers were examined for BRCA1/2, thus pre-
cluding the ability to derive a conclusion about the clin-
ical differences between BRCA and non-BRCA patients.
Conclusions
We demonstrated that TNBC is more common among
young patients below 60 years of age. The overall sur-
vival was significantly higher among nulliparous TNBC
patients and correlated inversely with the number of
births. Further prospective studies should reaffirm our
findings and explore the effect of genetic profiling and
ethnicity on the clinical course of TNBC patients.
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